drugset / Trial / NCT02162849

Reward Sensitivity and Pharmacotherapy for Smoking Cessation

NCT02162849

Phase 4 Active not recruiting 204 enrolled M.D. Anderson Cancer Center NAL PHARMA · collabPfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical research study is learn if varenicline or the nicotine patch can help people with different types of emotion and attention levels to quit smoking.

Timeline

Start
2015-12-14
Primary completion
2028-02-28
Completion
2028-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicotine Patch Unknown 21 mg Topical
Subject Varenicline Small molecule 1 mg Oral

Indications